N-(6-chloro-4-(4,4-difluoropiperidin-1-yl)pyridin-3-yl)-2-phenylimidazo[1,2-b]pyridazine-8-carboxamide

ID: ALA5278224

Chembl Id: CHEMBL5278224

Max Phase: Preclinical

Molecular Formula: C23H19ClF2N6O

Molecular Weight: 468.90

Names and Identifiers

Canonical SMILES:  O=C(Nc1cnc(Cl)cc1N1CCC(F)(F)CC1)c1ccnn2cc(-c3ccccc3)nc12

Standard InChI:  InChI=1S/C23H19ClF2N6O/c24-20-12-19(31-10-7-23(25,26)8-11-31)17(13-27-20)30-22(33)16-6-9-28-32-14-18(29-21(16)32)15-4-2-1-3-5-15/h1-6,9,12-14H,7-8,10-11H2,(H,30,33)

Standard InChI Key:  MVWZHDGRFGABKP-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA5278224

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 468.90

Molecular Weight (Monoisotopic): 468.1277

AlogP: 4.93

#Rotatable Bonds: 4

Polar Surface Area: 75.42

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.98

CX Basic pKa: 4.02

CX LogP: 4.56

CX LogD: 4.56

Aromatic Rings: 4

Heavy Atoms: 33

QED Weighted: 0.43

Np Likeness Score: -1.68

References

1. Hartz RA, Ahuja VT, Sivaprakasam P, Xiao H, Krause CM, Clarke WJ, Kish K, Lewis H, Szapiel N, Ravirala R, Mutalik S, Nakmode D, Shah D, Burton CR, Macor JE, Dubowchik GM..  (2023)  Design, Structure-Activity Relationships, and In Vivo Evaluation of Potent and Brain-Penetrant Imidazo[1,2-b]pyridazines as Glycogen Synthase Kinase-3β (GSK-3β) Inhibitors.,  66  (6): [PMID:36950863] [10.1021/acs.jmedchem.3c00133]

Source

Source(1):

• Scientific Literature